TY - JOUR
T1 - A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
AU - UK10K Consortium
AU - Timpson, Nicholas J.
AU - Walter, Klaudia
AU - Min, Josine L.
AU - Tachmazidou, Ioanna
AU - Malerba, Giovanni
AU - Shin, So Youn
AU - Chen, Lu
AU - Futema, Marta
AU - Southam, Lorraine
AU - Iotchkova, Valentina
AU - Cocca, Massimiliano
AU - Huang, Jie
AU - Memari, Yasin
AU - McCarthy, Shane
AU - Danecek, Petr
AU - Muddyman, Dawn
AU - Mangino, Massimo
AU - Menni, Cristina
AU - Perry, John R.B.
AU - Ring, Susan M.
AU - Gaye, Amadou
AU - Dedoussis, George
AU - Farmaki, Aliki Eleni
AU - Burton, Paul
AU - Talmud, Philippa J.
AU - Gambaro, Giovanni
AU - Spector, Tim D.
AU - Smith, George Davey
AU - Durbin, Richard
AU - Richards, J. Brent
AU - Humphries, Steve E.
AU - Zeggini, Eleftheria
AU - Soranzo, Nicole
AU - Turki, Saeed Al
AU - Anderson, Carl
AU - Anney, Richard
AU - Antony, Dinu
AU - Artigas, Maria Soler
AU - Ayub, Muhammad
AU - Balasubramaniam, Senduran
AU - Barrett, Jeffrey C.
AU - Barroso, Iněs
AU - Beales, Phil
AU - Bentham, Jamie
AU - Bhattacharya, Shoumo
AU - Birney, Ewan
AU - Blackwood, Douglas
AU - Bobrow, Martin
AU - Bochukova, Elena
AU - Bolton, Patrick
N1 - Funding Information:
This study makes use of data generated by the UK10K Consortium, derived from samples from the ALSPAC and TwinsUK data sets. A full list of the investigators who contributed to the generation of the data is available from www.UK10K.org. Funding for UK10K was provided by the Wellcome Trust under award WT091310. This work made use of data and samples generated by the 1958 Birth Cohort (NCDS). Access to these resources was enabled via the 58READIE Project funded by Wellcome Trust and Medical Research Council (grant numbers WT095219MA and G1001799). A full list of the financial, institutional and personal contributions to the development of the 1958 Birth Cohort Biomedical resource is available at www2.le.ac.uk/projects/birthcohort. Genotyping was undertaken as part of the Wellcome Trust Case-Control Consortium (WTCCC) under Wellcome Trust award 076113, and a full list of the investigators who contributed to the generation of the data is available at www.wtccc.org.uk. We also are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol provide core support for ALSPAC. TwinsUK was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR. S.S. is supported by an Oak Foundation Research Fellowship. N.S. is supported by the Wellcome Trust (Grant Codes WT098051 and WT091310), the EU FP7 (EPIGENESYS Grant Code 257082 and BLUEPRINT Grant Code HEALTH-F5-2011-282510). This work was also supported by the Wellcome Trust (098051) and the European Research Council (ERC-2011-StG 280559-SEPI). We are grateful to the residents of the Pomak villages and of the Mylopotamos villages for taking part in the HELIC study, and to Echinos Medical Centre and Anogia Medical Centre for their contribution to the collection. S.E.H. and M.F. are supported by the British Heart Foundation (PG008/08). NJT and GDS work within an MRC Unit at the University of Bristol (MC_UU_12013/1–9).
PY - 2014
Y1 - 2014
N2 - The analysis of rich catalogues of genetic variation from population-based sequencing provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3 (rs138326449-A, minor allele frequency ∼0.25% (UK)) associated with plasma triglyceride (TG) levels (-1.43 s.d. (s.e.=0.27 per minor allele (P-value=8.0 × 10 -8)) discovered in 3,202 individuals with low read-depth, whole-genome sequence. We replicate this in 12,831 participants from five additional samples of Northern and Southern European origin (-1.0 s.d. (s.e.=0.173), P-value=7.32 × 10 -9). This is consistent with an effect between 0.5 and 1.5 mmol l -1 dependent on population. We show that a single predicted splice donor variant is responsible for association signals and is independent of known common variants. Analyses suggest an independent relationship between rs138326449 and high-density lipoprotein (HDL) levels. This represents one of the first examples of a rare, large effect variant identified from whole-genome sequencing at a population scale.
AB - The analysis of rich catalogues of genetic variation from population-based sequencing provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3 (rs138326449-A, minor allele frequency ∼0.25% (UK)) associated with plasma triglyceride (TG) levels (-1.43 s.d. (s.e.=0.27 per minor allele (P-value=8.0 × 10 -8)) discovered in 3,202 individuals with low read-depth, whole-genome sequence. We replicate this in 12,831 participants from five additional samples of Northern and Southern European origin (-1.0 s.d. (s.e.=0.173), P-value=7.32 × 10 -9). This is consistent with an effect between 0.5 and 1.5 mmol l -1 dependent on population. We show that a single predicted splice donor variant is responsible for association signals and is independent of known common variants. Analyses suggest an independent relationship between rs138326449 and high-density lipoprotein (HDL) levels. This represents one of the first examples of a rare, large effect variant identified from whole-genome sequencing at a population scale.
UR - http://www.scopus.com/inward/record.url?scp=84923648340&partnerID=8YFLogxK
U2 - 10.1038/ncomms5871
DO - 10.1038/ncomms5871
M3 - Article
C2 - 25225788
AN - SCOPUS:84923648340
SN - 2041-1723
VL - 5
JO - Nature Communications
JF - Nature Communications
M1 - 4871
ER -